322 related articles for article (PubMed ID: 23470864)
1. Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
Yasuoka S; Kai H; Kajimoto H; Kudo H; Takayama N; Anegawa T; Koga M; Miyamoto T; Mifune H; Kage M; Hirooka Y; Imaizumi T
Circ J; 2013; 77(6):1474-81. PubMed ID: 23470864
[TBL] [Abstract][Full Text] [Related]
2. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.
Kudo H; Kai H; Kajimoto H; Koga M; Takayama N; Mori T; Ikeda A; Yasuoka S; Anegawa T; Mifune H; Kato S; Hirooka Y; Imaizumi T
Hypertension; 2009 Oct; 54(4):832-8. PubMed ID: 19704105
[TBL] [Abstract][Full Text] [Related]
3. Large blood pressure variability and hypertensive cardiac remodeling--role of cardiac inflammation.
Kai H; Kudo H; Takayama N; Yasuoka S; Kajimoto H; Imaizumi T
Circ J; 2009 Dec; 73(12):2198-203. PubMed ID: 19875896
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways.
Takayama N; Kai H; Kudo H; Yasuoka S; Mori T; Anegawa T; Koga M; Kajimoto H; Hirooka Y; Imaizumi T
Hypertens Res; 2011 Mar; 34(3):341-7. PubMed ID: 21124329
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of aggravation of hypertensive organ damages by short-term blood pressure variability.
Kai H; Kudo H; Takayama N; Yasuoka S; Aoki Y; Imaizumi T
Curr Hypertens Rev; 2014; 10(3):125-33. PubMed ID: 25544288
[TBL] [Abstract][Full Text] [Related]
7. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
[TBL] [Abstract][Full Text] [Related]
9. Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
Nakagaki T; Hirooka Y; Matsukawa R; Nishihara M; Nakano M; Ito K; Hoka S; Sunagawa K
Hypertens Res; 2012 Apr; 35(4):470-6. PubMed ID: 22237482
[TBL] [Abstract][Full Text] [Related]
10. Large blood pressure variability aggravates arteriolosclerosis and cortical sclerotic changes in the kidney in hypertensive rats.
Aoki Y; Kai H; Kajimoto H; Kudo H; Takayama N; Yasuoka S; Anegawa T; Iwamoto Y; Uchiwa H; Fukuda K; Kage M; Kato S; Fukumoto Y; Imaizumi T
Circ J; 2014; 78(9):2284-91. PubMed ID: 24976508
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Franco V; Chen YF; Feng JA; Li P; Wang D; Hasan E; Oparil S; Perry GJ
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):773-9. PubMed ID: 16922805
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.
Downey RM; Mizuno M; Mitchell JH; Vongpatanasin W; Smith SA
Am J Physiol Heart Circ Physiol; 2017 Oct; 313(4):H788-H794. PubMed ID: 28733447
[TBL] [Abstract][Full Text] [Related]
13. The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
Tsukamoto O; Minamino T; Sanada S; Okada K; Hirata A; Fujita M; Shintani Y; Yulin L; Asano Y; Takashima S; Yamasaki S; Tomoike H; Hori M; Kitakaze M
Cardiovasc Drugs Ther; 2006 Apr; 20(2):93-102. PubMed ID: 16761190
[TBL] [Abstract][Full Text] [Related]
14. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Endemann DH; Touyz RM; Iglarz M; Savoia C; Schiffrin EL
Hypertension; 2004 Jun; 43(6):1252-7. PubMed ID: 15117913
[TBL] [Abstract][Full Text] [Related]
15. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
[TBL] [Abstract][Full Text] [Related]
16. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Tanabe A; Naruse M; Hara Y; Sato A; Tsuchiya K; Nishikawa T; Imaki T; Takano K
J Hypertens; 2004 May; 22(5):1017-23. PubMed ID: 15097243
[TBL] [Abstract][Full Text] [Related]
18. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.
López-Andrés N; Martin-Fernandez B; Rossignol P; Zannad F; Lahera V; Fortuno MA; Cachofeiro V; Díez J
Am J Physiol Heart Circ Physiol; 2011 Dec; 301(6):H2372-82. PubMed ID: 21926338
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation.
Veliotes DG; Woodiwiss AJ; Deftereos DA; Gray D; Osadchii O; Norton GR
Hypertension; 2005 May; 45(5):914-20. PubMed ID: 15837836
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone target organ protection by eplerenone.
Rudolph AE; Rocha R; McMahon EG
Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
